Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(50%)

Terminated

1(25%)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Terminated(1)

Detailed Status

Recruiting2

Not yet recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

recruiting250%

not_yet_recruiting125%

terminated125%

Recent Activity

2 active trials

Showing 4 of 4

not_yet_recruitingphase_1

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT07430202

recruitingphase_1

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT06027086

recruitingphase_2

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

NCT07249372

terminatedphase_1

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

NCT04471415

Clinical Trials (4)

Showing 4 of 4 trials

NCT07430202Phase 1

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Not Yet Recruiting

NCT06027086Phase 1

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Recruiting

NCT07249372Phase 2

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Recruiting

NCT04471415Phase 1

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4